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Introduction
The progressive degenerative changes associated with
osteoarthritis (OA) can arise from age-related chronic
degeneration or can be triggered by traumatic changes in
the articular cartilage and/or subchondral bone. Traditionally,
the orthopaedics industry has intervened in this disease
progression only in the latter stages with joint replacements,
but the picture has been changing over the last few years with
the development of novel products and techniques. In addition
to arthroplasty, the orthopaedics industry is now considering
three alternative points of intervention in the disease, namely:
(1) pain treatment; (2) disease progression; and (3) treatment
of cartilage and osteochondral trauma, all essentially allowing
for preservation of the joint. Whilst joint arthroplasty remains
an extremely successful treatment option, a realistic aim of the
healthcare industry must be to prevent disease progression,
throughearlyinterventionallowingforamorecompletereturn
to function for patients.
Industry Innovations in Pain Management in OA
Treatment of OA pain has been largely the domain of
pharmaceutical companies, but over the last few years, a
number of orthopaedic players have developed intra-
articular injections of hyaluronic acid (HA) for treatment
of pain. Adoption of this technology has suffered to some
extent due to the requirement for a course of multiple
injections and reports of pseudosepsis. Newer formulations
are now becoming available that require only a single
injection, with pain relief lasting for several months and no
apparent incidence of pseudosepsis [3].
The provision of such HA products by orthopaedic
companies is a radical change from the traditional “metal
and plastic” of previous years, and a natural extension to
this will be for companies to provide similar products that
can slow or arrest disease development. Although no such
products are currently available, it is an area of active
research.
Industry Innovations in Cartilage Repair
Perhaps the most signiﬁcant advances in OA by orthopaedic
companies have resulted from approaches to the surgical
treatment of chondral and osteochondral lesions or cartilage
restoration. A variety of approaches exist for treating these
lesions, mostly using autograft tissue (e.g., OATS or
autologous chondrocyte implantation procedures) or allo-
graft tissue, but each has limitations. Zimmer has recently
introduced two new implants to provide a therapeutic
cartilage repair whilst avoiding some of the pitfalls of other
techniques: DeNovo NT® Natural Tissue Graft is an
allograft composed of particulated live juvenile cartilage
containing viable chondrocytes. It has been well reported
that the metabolic activity of juvenile cells is signiﬁcantly
higher than adult cells [1], and consequently, it might be
expected that the repair may be improved over other
methods. To date, approximately 2,500 cases have been
conducted with this allograft, and initial clinical results
appear extremely promising [2] through 2 years of follow-up.
Osteochondral allografts have provided a good option for
repair for over three decades, but have been reported to induce
immune responses to the graft, leading to prolonged inﬂam-
matory reactions, cartilage degeneration and delayed graft
incorporation. A recently introduced product (Chondroﬁx®
OsteochondralAllograft)seemstobelesspronetotheseissues
owing to the removal of lipids and other cell debris.
Additionally, this product has the advantage of a 2-year shelf
life whilst retaining all mechanical properties of native tissue.
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Summary
The intention of these newer implants is the treatment of
cartilage lesions as soon as they become symptomatic and
returning the patient to a level of function as high as that
achieved prior to injury. As technology advances, we might
expect to see the emergence of disease-modifying treatments
for OA, further improvements in pain medication and also the
emergenceofgenuinelyefﬁcacioustissue-engineeredchondral
repair products. A number of these are currently in phase 3
clinical studies.
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